A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV‐2 (COVID‐19) DHODH (dihydroorotate dehydrogenase) inhibitor

A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV‐2 (COVID‐19) DHODH (dihydroorotate dehydrogenase) inhibitor

Abstract A therapeutic agent that targets both viral replication and the hyper‐reactive immune response would offer a highly desirable treatment for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; COVID‐19) management. Emvododstat (PTC299) was found to be a potent inhibitor of immunomod...

Full description

Bibliographic Details
Main Authors: Terri L. Morton, Oscar L. Laskin, Diksha Kaushik, Lucy Lee, Jiyuan Ma, Allan Kristensen, Kylie O'Keefe, Lee Golden, Matthew Klein, Ronald Kong
Format: Article
Language:English
Published: Wiley 2023-04-01
Series:Pharmacology Research & Perspectives
Subjects:
BCRP
coronavirus
COVID‐19
DHODH
pharmacokinetics
PTC299
Online Access:https://doi.org/10.1002/prp2.1076

Internet

https://doi.org/10.1002/prp2.1076

Similar Items